Press release
PCSK9 Inhibitor Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies involved by DelveInsight | Ionis Pharmaceuticals, Akeso Biopharma, Amgen, Novo Nordisk, Civi BioPharma
PCSK9 Inhibitor Pipeline
In the PCSK9 Inhibitor Pipeline Report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, PCSK9 Inhibitor NDA approvals (if any), and product development activities comprising the technology, PCSK9 Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the PCSK9 Inhibitor Pipeline treatment landscape of the report, click here @ PCSK9 Inhibitor Pipeline Outlook- https://www.delveinsight.com/report-store/proprotein-convertase-subtilisin-kexin-type-9-pcsk9-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the PCSK9 Inhibitor Pipeline Report
• DelveInsight's PCSK9 Inhibitor Pipeline analysis depicts a robust space with 14+ active players working to develop 14+ pipeline treatment therapies.
• The leading companies are working in the PCSK9 Inhibitor market include Ionis Pharmaceuticals, Akeso Biopharma, Amgen, Novo Nordisk, Civi BioPharma, and others.
• Promising PCSK9 Inhibitor Pipeline Therapies in the various stages of development include AK102, Statins, Ezetimibe, MK-0616, Bempedoic Acid 180 mg, Evolocumab, IBI306, and others.
• On March 2023, LIB Therapeutics LLC announced a study of phase 3 clinical trials for lerodalcibep. The study is to assess the long-term safety, tolerability, and efficacy after 48 and 72 weeks with monthly (Q4W [
• On July 2023, Brigham and Women's Hospital announced a study of phase 4 clinical trials for Evolocumab and Statins (Cardiovascular Agents). The study would involve a total of 120 patients across 3 different hospitals in Boston, Massachusetts.
PCSK9 Inhibitor Overview
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is a serine protease involved in cholesterol homeostasis. After binding to the complex low-density lipoprotein (LDL)-receptor, PCSK9 induces its intracellular degradation, thus reducing serum LDL clearance.
For further information, refer to the detailed PCSK9 Inhibitor Unmet Needs, click here for PCSK9 Inhibitor Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/proprotein-convertase-subtilisin-kexin-type-9-pcsk9-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
PCSK9 Inhibitor Emerging Drugs Profile
• Evolocumab: Amgen
Evolocumab (Repatha) is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It is being investigated for the treatment of patients with high-risk cardiovascular disease without prior heart attack or stroke. It is being investigated for the treatment of familial hypercholesterolemia in pediatric patients.
• ION449: Ionis Pharmaceuticals
ION449 (formerly IONIS-AZ4-2.5-LRx), also known as AZD8233, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is integrally involved in the regulation of LDL-cholesterol. Genetic studies have shown that individuals with life-long reduction of LDL-C due to reduced function of PCSK9 have substantially reduced risk of cardiovascular disease. Pharmacological inhibition of PCSK9 substantially lowers LDL-C. ION449 is designed to reduce the liver production of PCSK9 and lower the plasma level of LDL-C and thus reduce the risk of cardiovascular disease.
PCSK9 Inhibitor Therapeutics Assessment
There are approx. 14+ key companies which are developing the therapies for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor. The PCSK9 Inhibitor companies which have their Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Amgen.
Request a sample and discover the recent advances in PCSK9 Inhibitor Ongoing Clinical Trial Analysis and Medications, Click here for more details @ PCSK9 Inhibitor Segmentation- https://www.delveinsight.com/sample-request/proprotein-convertase-subtilisin-kexin-type-9-pcsk9-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
PCSK9 Inhibitor Drugs and Companies
• AK102: Akeso
• Statins: AD Pharmaceuticals Co. Ltd
• MK-0616: Merck Sharp & Dohme LLC
PCSK9 Inhibitor Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the PCSK9 Inhibitor Therapeutics Market include-
Ionis Pharmaceuticals, Akeso Biopharma, Amgen, Novo Nordisk, Civi BioPharma, and others.
Dive deep into rich insights for drugs for PCSK9 Inhibitor Pipeline, click here @ PCSK9 Inhibitor Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/proprotein-convertase-subtilisin-kexin-type-9-pcsk9-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the PCSK9 Inhibitor Pipeline Report
• Coverage- Global
• PCSK9 Inhibitor Companies- Ionis Pharmaceuticals, Akeso Biopharma, Amgen, Novo Nordisk, Civi BioPharma, and others.
• PCSK9 Inhibitor Therapies- AK102, Statins, Ezetimibe, MK-0616, Bempedoic Acid 180 mg, Evolocumab, IBI306, and others.
• PCSK9 Inhibitor Market Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on PCSK9 Inhibitor Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/proprotein-convertase-subtilisin-kexin-type-9-pcsk9-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Evolocumab: Amgen
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. ION449: Ionis Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. Drug Name: Company Name
14. Drug profiles in the detailed report…..
15. Preclinical stage products
16. Oral PCSK9 inhibitor: Esperion Therapeutics
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Key Companies
20. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Key Products
21. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor- Unmet Needs
22. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor- Market Drivers and Barriers
23. Appendix
Trending Reports:
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Ambulatory Arrhythmia Monitoring Devices Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market
• Choroidal Neovascularization Market: https://www.delveinsight.com/report-store/choroidal-neovascularization-market
• Pruritus Market: https://www.delveinsight.com/report-store/pruritus-market
• Cardiopulmonary Bypass Equipment Market: https://www.delveinsight.com/report-store/cardiopulmonary-bypass-equipment-market
• Chemotherapy Induced Anemia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Clbp Market: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Pemphigus Vulgaris Market: https://www.delveinsight.com/infographics/pemphigus-vulgaris-market
• Polycythemia Vera Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Advanced Renal Cell Carcinoma Market: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Angioedema Market: https://www.delveinsight.com/report-store/angioedema-market
• Bladder Pain Syndrome Market: https://www.delveinsight.com/report-store/interstitial-cystitis-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/brain-aneurysm-stents-market
• Calciphylaxis Market: https://www.delveinsight.com/report-store/calciphylaxis-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Inflammtory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Cutaneous T-cell Lymphoma Market: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/dermal-erythema-market
• Eczema Market: https://www.delveinsight.com/report-store/atopic-dermatitis-market
Contact Info:
Ankit Nigam
Assistant Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release PCSK9 Inhibitor Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies involved by DelveInsight | Ionis Pharmaceuticals, Akeso Biopharma, Amgen, Novo Nordisk, Civi BioPharma here
News-ID: 3469033 • Views: …
More Releases from DelveInsight Business Research
Erectile Dysfunction Market Growth Outlook 2034: Epidemiology, Pipeline Therapie …
DelveInsight's "Erectile Dysfunction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Erectile Dysfunction, historical and forecasted epidemiology as well as the Erectile Dysfunction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Erectile Dysfunction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Erectile Dysfunction Market Forecast
https://www.delveinsight.com/sample-request/erectile-dysfunction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav
Some of the…
Degenerative Disc Disease Pipeline 2026: FDA Approvals and Clinical Trials Lands …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Degenerative Disc Disease pipeline constitutes 15+ key companies continuously working towards developing 15+ Degenerative Disc Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Degenerative Disc Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.…
Charcot Marie Tooth Disease Pipeline 2026: Therapies, MOA Insights, and Key Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Charcot Marie Tooth Disease pipeline constitutes 13+ key companies continuously working towards developing 15+ Charcot Marie Tooth Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Charcot Marie Tooth Disease Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across…
Stargardt Disease Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Stargardt Disease pipeline constitutes 20+ key companies continuously working towards developing 20+ Stargardt Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Stargardt Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
More Releases for PCSK9
PCSK9 Inhibitors Market Growth: Revolutionizing Modern Cholesterol Management
The global PCSK9 Inhibitors Market is experiencing significant momentum as healthcare systems worldwide intensify efforts to address cardiovascular diseases and cholesterol-related disorders. PCSK9 inhibitors have emerged as a groundbreaking class of lipid-lowering therapies, offering effective treatment options for patients who require substantial reductions in low-density lipoprotein cholesterol (LDL-C) levels. Growing awareness regarding preventive cardiovascular care, coupled with advances in precision medicine, is accelerating the adoption of these therapies across developed…
PCSK9 Inhibitors Market Is Going to Boom |• Amgen • Sanofi
According to Worldwide Market Reports (WMR) highlights that the "PCSK9 Inhibitors Market" is projected to experience substantial growth in the coming years. This report provides a comprehensive analysis of the market landscape using an integrated approach that includes research methodology, market size evaluation, data compilation, and insights gathered from multiple credible sources.
The study covers critical market elements such as market dynamics, drivers, restraints, challenges, threats, growth opportunities, development trends, technological…
PCSK9 Inhibitors Market is projected to reach USD 19.64 billion by 2034
The global PCSK9 Inhibitors Market was valued at USD 6.98 billion in 2024 and is projected to reach USD 19.64 billion by 2034, growing at a CAGR of 10.8% during the forecast period (2025-2034). The market is driven by the rising global burden of cardiovascular disease, increasing incidence of hypercholesterolemia, broader guideline recommendations for LDL-C lowering, and expanded use of biologics and RNA-based therapies targeting the PCSK9 pathway.
Download Full PDF…
PCSK9 Inhibitors Market Growth, Applications, Innovations and Business Outlook b …
Introduction
Cardiovascular diseases remain the leading cause of mortality worldwide, with elevated low-density lipoprotein cholesterol (LDL-C) being one of the most significant risk factors. While statins have long been the cornerstone of lipid-lowering therapy, many patients experience inadequate response or intolerance. This has driven the emergence of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors as a breakthrough class of drugs, offering dramatic LDL-C reductions and improved cardiovascular outcomes.
PCSK9 inhibitors work by…
PCSK9 Inhibitors Market Poised for Significant Growth by 2034, Predicts DelveIns …
The PCSK9 Inhibitors market is steadily advancing, driven by evolving treatment strategies and ongoing research. DelveInsight's latest 7MM report offers in-depth insights into key epidemiology trends and market dynamics.
DelveInsight's "PCSK9 Inhibitors - Market Insight, Epidemiology, And Market Forecast - 2034 [https://www.delveinsight.com/report-store/pcsk9-inhibitors-psck9i-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr] report offers an in-depth understanding of the PCSK9 Inhibitors, historical and forecasted epidemiology as well as the PCSK9 Inhibitors market trends in the United States, EU5 (Germany, Spain, Italy,…
PCSK9 Inhibitor Pipeline Insights Report 2024
(Albany, United States) As per DelveInsight's assessment, globally, the PCSK9 Inhibitor Pipeline constitutes 14+ key companies continuously working towards developing 14+ PCSK9 Inhibitor Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the PCSK9 Inhibitor Pipeline Report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, PCSK9 Inhibitor NDA approvals (if any),…
